Certara announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s Center for Drug Evaluation and Review were received by Certara’s customers in 2022. This is the 9th consecutive year that Certara’s customers, who use the Company’s biosimulation software and technology-driven services, have had novel drugs approved by the FDA in a wide range of therapeutic indications, from oncology to rare diseases.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CERT:
- Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
- Certara initiated with an Overweight at Stephens
- Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
- Certara downgraded to Equal Weight from Overweight at Barclays
- Certara price target raised to $27 from $22 at Credit Suisse
